← Back to Search

Unknown

Part 1, ABBV-903 for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by AbbVie
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to day 66
Awards & highlights

Study Summary

This trial tests a drug's safety and how it moves in the body in healthy adults.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to day 66
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to day 66 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Apparent Terminal Phase Elimination Constant (β)
Area Under the Plasma Concentration-time Curve (AUC)
Area Under the Plasma Concentration-time Curve from Time 0 Until Infinity (AUCinf)
+5 more

Trial Design

6Treatment groups
Experimental Treatment
Group I: Part 3, Sequence 2Experimental Treatment2 Interventions
Participants in Part 3 will follow Sequence 2.
Group II: Part 3, Sequence 1Experimental Treatment2 Interventions
Participants in Part 3 will follow Sequence 1.
Group III: Part 2, PlaceboExperimental Treatment1 Intervention
Participants will receive multiple ascending doses of placebo in Part 2.
Group IV: Part 2, ABBV-903Experimental Treatment1 Intervention
Participants will receive multiple ascending doses of ABBV-903 in Part 2.
Group V: Part 1, PlaceboExperimental Treatment1 Intervention
Participants will receive a single ascending dose of placebo in Part 1.
Group VI: Part 1, ABBV-903Experimental Treatment1 Intervention
Participants will receive a single ascending dose of ABBV-903 in Part 1.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Placebo for ABBV-903
2023
Completed Phase 1
~110
ABBV-903
2023
Completed Phase 1
~140
Itraconazole
2017
Completed Phase 2
~780

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

AbbVieLead Sponsor
954 Previous Clinical Trials
501,001 Total Patients Enrolled
ABBVIE INC.Study DirectorAbbVie
394 Previous Clinical Trials
145,835 Total Patients Enrolled

Media Library

ABBV-903 (Unknown) Clinical Trial Eligibility Overview. Trial Name: NCT05691699 — Phase 1
Healthy Subjects Research Study Groups: Part 2, Placebo, Part 1, ABBV-903, Part 2, ABBV-903, Part 3, Sequence 1, Part 1, Placebo, Part 3, Sequence 2
Healthy Subjects Clinical Trial 2023: ABBV-903 Highlights & Side Effects. Trial Name: NCT05691699 — Phase 1
ABBV-903 (Unknown) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05691699 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the age limit for enrollment in this trial greater than 25 years old?

"According to the trial's enrollment requirements, individuals aged 18 or older and under 65 are eligible for participation."

Answered by AI

Has Part 1 of the ABBV-903 drug trial met all regulatory requirements by the FDA?

"Due to the preliminary nature of this clinical trial, ABBV-903's safety rating was assigned a score of 1. This phase one investigation has little data backing its efficacy and safety."

Answered by AI

What is the current status for enrolment in this experiment?

"Confirmed. The details available on clinicaltrials.gov show that this research project is in the process of recruiting participants, with an initial posting date of March 1st 2023 and a recent update dated January 18th 2023."

Answered by AI

How many individuals are taking part in this experiment?

"Affirmative. As indicated on clinicaltrials.gov, this medical trial is currently initiating recruitment and was first published on the 3rd of January 2023 with a subsequent update made 18 days later. Participants are required from 1 specific site, totalling 84 enrolments in total."

Answered by AI

Is there an opportunity for me to take part in this medical experiment?

"This research requires 84 individuals aged 18-65 with a good overall health status. Specifically, the criteria includes body mass index between 18 and 32 kg/m2 after rounding to the nearest tenth at screening as well as during initial confinement in addition to an assessment of medical history, physical exam, vital signs, lab profile and electrocardiogram (ECG)."

Answered by AI

Who else is applying?

What state do they live in?
Illinois
What site did they apply to?
Acpru /Id# 251279
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
A Study to Assess Adverse Events and How Single and Multiple Ascending Doses of ABBV-903 Move Through the Body in Healthy Adults
2023. "A Study to Assess Adverse Events and How Single and Multiple Ascending Doses of ABBV-903 Move Through the Body in Healthy Adults". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05691699.
~46 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top